Table 2.
Outcomes by baseline patient characteristics
| Number/deaths (% dying within strata) n/N (%) |
RR (95%CI) | |
|---|---|---|
| Total mortality | 28/329 (9)* | — |
| Type of clinic | ||
| Without attached HIV clinic | 20/250 (8) | |
| With attached HIV clinic | 8/79 (10) | 0.79 (0.36–1.7) |
| Sex | ||
| Female | 15/149 (10) | |
| Male | 13/180 (7) | 1.4 (0.69–2.8) |
| Age, years | ||
| <35 | 10/144 (7) | |
| ≥35 | 18/185 (10) | 0.71 (0.34–1.50) |
| Baseline CD4 count, cells/mm3 | ||
| <100 | 23/173 (13) | |
| >100 | 5/1 56 (3) | 4.15 (1.62–10.65) |
| Baseline sputum status | ||
| Positive | 10/147 (7) | |
| Negative or not recorded | 18/182 (10) | 0.69 (0.33–1.44) |
| Initiated anti-tuberculosis treatment as in-patient |
||
| Yes | 6/57 (11) | |
| No | 22/272 (8) | 1.3 (0.55–3.06) |
| Initiated HAART within 60 days of starting anti-tuberculosis treatment |
||
| Yes | 1/86 (1) | |
| No | 3/97 (3) | 0.38 (0.04–3.55) |
*
As 10 patients were lost to follow-up, mortality calculations are based on a patient population of 329.
RR = relative risk; CI = confidence interval; HAART = highly active antiretroviral therapy.